Patent covering the use and pharmaceutical composition of Isofol’s lead Drug candidate, Modufolin®, allowed by United States Patent and Trademark Office
Isofol Medical AB today announced that the United States Patent and Trademark Office has allowed Isofol’s patent No. 12/805,287, covering the use and pharmaceutical composition of [6R]-methylene-tetrahydrofolate (Modufolin®), to reduce toxicity resulting from multi-targeting antifolate chemotherapy. Isofol provided evidence demonstrating the clear superiority of Modufolin® over folic acid in reducing pemetrexed toxicity. “I am very …
